1. Safety and efficacy of the rSh28GST urinary schistosomiasis vaccine: A phase 3 randomized, controlled trial in Senegalese children
- Author
-
Riveau, Gilles, Schacht, Anne-Marie, Dompnier, Jean-Pierre, Deplanque, Dominique, Seck, Modou, Waucquier, Nawal, Senghor, Simon, Delcroix-Genete, Delphine, Hermann, Emmanuel, Idris-Khodja, Noureddine, Levy-Marchal, Claire, Capron, Monique, Capron, André, Centre de Recherche Biomédicale Espoir Pour La Santé [Saint-Louis, Sénégal] (CRB EPLS), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Centre d'Investigation Clinique - Innovation Technologique de Lille - CIC 1403 - CIC 9301 (CIC Lille), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Regenerative Nanomedicine [Strasbourg] (RNM), Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA)-Université de Strasbourg (UNISTRA), Pôle de Recherche Clinique [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM), Lille Inflammation Research International Center - U 995 (LIRIC), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Institut Pasteur de Lille, Académie des Sciences, Institut de France, This work was supported by Région Nord-Pas de Calais (France), Inserm (France), Coopération Internationale, Principauté de Monaco, Région Wallonne (Belgium), Ministère des Affaires Etrangères et Européennes (France), Agence de l’Eau Artois-Picardie (France), Crédit Mutuel Nord Europe (France), Véolia Environnement (France), Région Midi-Pyrénées (France), Région Rhône-Alpes (France), Lesaffre Group (France) and Région Saint Louis (Senegal)., Bodescot, Myriam, Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), and Académie des Sciences [Paris]
- Subjects
Physiology ,RC955-962 ,Urine ,Biochemistry ,Schistosomiasis haematobia ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Arctic medicine. Tropical medicine ,Immune Physiology ,Medicine and Health Sciences ,Schistosomiasis ,Public and Occupational Health ,Child ,Immune Response ,Glutathione Transferase ,Vaccines, Synthetic ,Vaccines ,Immune System Proteins ,Incidence ,Vaccination ,Eukaryota ,Helminth Proteins ,Vaccination and Immunization ,Senegal ,Body Fluids ,Treatment Outcome ,Infectious Diseases ,Helminth Infections ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Schistosoma haematobium ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Schistosoma ,Public aspects of medicine ,RA1-1270 ,Anatomy ,Research Article ,Neglected Tropical Diseases ,[SDV.IMM] Life Sciences [q-bio]/Immunology ,Infectious Disease Control ,Immunology ,Antibodies ,Helminths ,parasitic diseases ,Parasitic Diseases ,Animals ,Humans ,Organisms ,Biology and Life Sciences ,Proteins ,Tropical Diseases ,Invertebrates ,Antigens, Helminth ,Preventive Medicine - Abstract
Background Urinary schistosomiasis, the result of infection by Schistosoma haematobium (Sh), remains a major global health concern. A schistosome vaccine could represent a breakthrough in schistosomiasis control strategies, which are presently based on treatment with praziquantel (PZQ). We report the safety and efficacy of the vaccine candidate recombinant 28-kDa glutathione S-transferase of Sh (rSh28GST) designated as Bilhvax, in a phase 3 trial conducted in Senegal. Methods and findings After clearance of their ongoing schistosomiasis infection with two doses of PZQ, 250 children aged 6–9 years were randomized to receive three subcutaneous injections of either rSh28GST/Alhydrogel (Bilhvax group) or Alhydrogel alone (control group) at week 0 (W0), W4, and W8 and then a booster at W52 (one year after the first injection). PZQ treatment was given at W44, according to previous phase 2 results. The primary endpoint of the analysis was efficacy, evaluated as a delay of recurrence of urinary schistosomiasis, defined by a microhematuria associated with at least one living Sh egg in urine from baseline to W152. During the 152-week follow-up period, there was no difference between study arms in the incidence of serious adverse events. The median follow-up time for subjects without recurrence was 22.9 months for the Bilhvax group and 18.8 months for the control group (log-rank p = 0.27). At W152, 108 children had experienced at least one recurrence in the Bilhvax group versus 112 in the control group. Specific immunoglobulin (Ig)G1, IgG2, and IgG4, but not IgG3 or IgA titers, were increased in the vaccine group. Conclusions While Bilhvax was immunogenic and well tolerated by infected children, a sufficient efficacy was not reached. The lack of effect may be the result of several factors, including interference by individual PZQ treatments administered each time a child was found infected, or the chosen vaccine-injection regimen favoring blocking IgG4 rather than protective IgG3 antibodies. These observations contrasting with results obtained in experimental models will help in the design of future trials. Trial registration ClinicalTrials.gov NCT 00870649, Author summary Vaccines represent an attractive tool in the fight against schistosomiasis. Pre-clinical immunization studies with the schistosome enzyme 28 kDa glutathione S-transferase (28GST) have shown a significant reduction of schistosome egg production and subsequent pathology. The objective of the present phase 3 trial was to assess the efficacy and safety of vaccination with the recombinant 28GST of Schistosoma haematobium (rSh28GST) named Bilhvax, in infected school children. After Praziquantel treatment before inclusion and three administrations of rSh28GST at one month interval as primo-vaccination, subjects received a boost injection one year after the first administration. The efficacy was evaluated as a delay of recurrence of urinary schistosomiasis. While immunological analysis showed that Bilhvax induced a consistent immune response characterized by antibodies able to inhibit 28GST enzymatic activity, the efficacy endpoint was not reached. This lack of significant effect may be due to the negative conjunction of a too challenging recurrence criterion associated with safety measures ensuring repeated PZQ treatment. The control of these main factors will be essential for the subsequent trials and must provide evidence of the Bilhvax efficacy as a safe vaccine against uro-genital schistosomiasis.
- Published
- 2018
- Full Text
- View/download PDF